Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,401–1,500 of 10,906
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19
Szarpak, L., Rafique, Z., Gąsecka, A., Chirico, F., Gaweł, W., Hernik, J., Kamińska, H., Filipiak, K. J., Jaguszewski, M. J., & Szarpak, Ł. (2021) · Cardiology Journal · doi:10.5603/cj.a2021.0072 · Cited by 59
Ye, Z., Yuan, S., Chan, J. F., Zhang, J., Yu, C.-Y., Ong, C. P., Yang, D., Chan, C. C.-Y., Tang, K., Cao, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1885998 · Cited by 53
Syversen, S. W., Jyssum, I., Tveter, A. T., Tran, T. T., Sexton, J., Provan, S. A., Mjaaland, S., Warren, D. J., Kvien, T. K., Grødeland, G., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42153 · Cited by 61
Salerno, L., Craxì, L., Amodio, E., & Coco, G. L. (2021) · Vaccines · doi:10.3390/vaccines9080927 · Cited by 66
Ferranna, M., Cadarette, D., & Bloom, D. E. (2021) · Engineering · doi:10.1016/j.eng.2021.03.014 · Cited by 55
Galanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., & Καϊτελίδου, Δ. (2021) · medRxiv · doi:10.1101/2021.07.28.21261261 · Cited by 58
Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
Shamier, M. C., Tostmann, A., Bogers, S., de Wilde, J., IJpelaar, J., van der Kleij, W. A., de Jager, H., Haagmans, B. L., Molenkamp, R., Oude Munnink, B. B., et al. (2021) · doi:10.1101/2021.08.20.21262158 · Cited by 56
Precision therapeutic targets for COVID-19
Krumm, Z. A., Lloyd, G. M., Francis, C. P., Nasif, L. H., Mitchell, D. A., Golde, T. E., Giasson, B. I., & Xia, Y. (2021) · Virology Journal · doi:10.1186/s12985-021-01526-y · Cited by 59
van Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100352 · Cited by 57
VILCHES, T. N., Moghadas, S. M., Sah, P., Fitzpatrick, M. C., Shoukat, A., Pandey, A., & Galvani, A. P. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.42725 · Cited by 55
A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
Heidari, S., Palmer-Ross, A., & Goodman, T. (2021) · Vaccines · doi:10.3390/vaccines9111322 · Cited by 57
Khaled, S. M., Petcu, C. G., Bader, L., Amro, I., Al-Hamadi, A. M., Al-Assi, M., Ali, A. A., Trung, K. L., Diop, A., Bellaj, T., et al. (2021) · Vaccines · doi:10.3390/vaccines9050471 · Cited by 62
A behavioural modelling approach to assess the impact of COVID-19 vaccine hesitancy
Buonomo, B., Marca, R. D., d’Onofrio, A., & Groppi, M. (2021) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2021.110973 · Cited by 58
Pušnik, J., Monzon‐Posadas, W. O., Zorn, J., Peters, K., Baum, M., Proksch, H., Schlüter, C. B., Alter, G., Menting, T., & Streeck, H. (2023) · Nature Communications · doi:10.1038/s41467-023-36250-4 · Cited by 57
Modeling the effect of the vaccination campaign on the COVID-19 pandemic
Angeli, M., Neofotistos, G., Mattheakis, M., & Kaxiras, E. (2021) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2021.111621 · Cited by 57
The art of prevention: COVID-19 vaccine preparedness for the dermatologist
Rice, S. M., Ferree, S. D., Mesinkovska, N. A., & Kourosh, A. S. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.01.007 · Cited by 56
COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
Iacopetta, D., Ceramella, J., Catalano, A. A., Saturnino, C., PELLEGRINO, M. A., Mariconda, A., Longo, P., Sinicropi, M. S., & Aquaro, S. (2022) · Viruses · doi:10.3390/v14030573 · Cited by 65
COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience
So, A. C. P., McGrath, H., Ting, J., Srikandarajah, K., Germanou, S., Moss, C. L., Russell, B. A., Monroy‐Iglesias, M. J., Dolly, S. O., Irshad, S., et al. (2021) · Cancers · doi:10.3390/cancers13143573 · Cited by 57
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 56
Fusco, M. D., Moran, M. M., Cane, A. D., Curcio, D., Khan, F. L., Malhotra, D., Surinach, A., Miles, A., Swerdlow, D. L., McLaughlin, J. M., et al. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.2002063 · Cited by 57
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 63
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
Kitagawa, H., Kaiki, Y., Sugiyama, A., Nagashima, S., Kurisu, A., Nomura, T., Omori, K., Akita, T., Shigemoto, N., Tanaka, J., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.034 · Cited by 56
Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development
Kim, D.-K., Lai, C., Cha, I., & Jung, J. U. (2024) · Viruses · doi:10.3390/v16010128 · Cited by 64
Delivery Routes for COVID-19 Vaccines
Park, J. H., & Lee, H. K. (2021) · Vaccines · doi:10.3390/vaccines9050524 · Cited by 56
Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19
Silva-Pilipich, N., Beloki, U., Salaberry, L., & Smerdou, C. (2024) · Vaccines · doi:10.3390/vaccines12030318 · Cited by 72
Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review
Koike, H., Chiba, A., & Katsuno, M. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00261-4 · Cited by 76
Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 56
Epsi, N. J., Richard, S. A., Lindholm, D. A., Mende, K., Ganesan, A., Huprikar, N., Lalani, T., Fries, A. C., Maves, R. C., Colombo, R. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac392 · Cited by 61
Min, Y. G., Ju, W., Ha, Y.-E., Ban, J., Lee, S., Sung, J., & Shin, J.-Y. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577691 · Cited by 55
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 67
Potential Effects of Coronaviruses on the Liver: An Update
Wang, X., Lei, J., Li, Z., & Yan, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.651658 · Cited by 57
Halwe, S., Kupke, A., Vanshylla, K., Liberta, F., Gruell, H., Zehner, M., Rohde, C., Krähling, V., Serra, M. G., Kreer, C., et al. (2021) · Viruses · doi:10.3390/v13081498 · Cited by 57
Altarawneh, H. N., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104734 · Cited by 58
Jacob, S., Varkey, N. R., Boddu, S. H. S., Gorain, B., Rao, R., & Nair, A. B. (2025) · Pharmaceuticals · doi:10.3390/ph18121772 · Cited by 82
“Lipid nanoparticles have become pivotal in advancing modern therapeutics, exemplified by their role in mRNA COVID-19 vaccines [191].”
Risk, M., Hayek, S. S., Schiopu, E., Yuan, L., Shen, C., Shi, X., Freed, G. L., & Zhao, L. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00216-8 · Cited by 55
Role of T cells in severe COVID-19 disease, protection, and long term immunity
Hermens, J. M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01294-9 · Cited by 60
A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19
Logette, E., Lorin, C., Favreau, C., Oshurko, E., Coggan, J. S., Casalegno, F., Sy, M. F., Monney, C., Bertschy, M., Delattre, É., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.695139 · Cited by 63
Skawran, S., Gennari, A. G., Dittli, M., Treyer, V., Muehlematter, U. J., Maurer, A. B., Burger, I. A., Mader, C. E., Messerli-Odermatt, O., Grünig, H., et al. (2021) · European Radiology · doi:10.1007/s00330-021-08122-2 · Cited by 55
Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models
Guimarães, L. C., Costa, P. A. C., Scalzo, S., Ferreira, H. A. S., Braga, A. C. S., de Oliveira, L. C., Figueiredo, M. M., Shepherd, S. J., Hamilton, A. G., Queiroz‐Junior, C. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44830-1 · Cited by 65
Jacobson, K. B., Pinsky, B. A., Montez Rath, M. E., Wang, H., Miller, J. A., Skhiri, M., Shepard, J., Mathew, R., Lee, G., Bohman, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab554 · Cited by 62
Self-citationTragni, V., Primiano, G., Tummolo, A., Beltrame, L. C., Piana, G. L., Sgobba, M. N., Cavalluzzi, M. M., Paterno, G., Gorgoglione, R., Volpicella, M., et al. (2022) · Molecules · doi:10.3390/molecules27113494 · Cited by 60
Complete protection by a single-dose skin patch–delivered SARS-CoV-2 spike vaccine
McMillan, C. L. D., Choo, J. J. Y., Idris, A., Supramaniam, A., Modhiran, N., Amarilla, A. A., Isaacs, A., Cheung, S. T. M., Liang, B., Bielefeldt‐Ohmann, H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj8065 · Cited by 57
Lombardi, A., Bozzi, G., Ungaro, R., Villa, S., Castelli, V., Mangioni, D., Muscatello, A., Gori, A., & Bandera, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657711 · Cited by 57
Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy
Yan, Y., Liu, X., Wang, L., Wu, C., Shuai, Q., Zhang, Y., & Liu, S. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122279 · Cited by 59
mRNA lipid nanoparticle formulation, characterization and evaluation
Ma, Y., VanKeulen-Miller, R., & Fenton, O. S. (2025) · Nature Protocols · doi:10.1038/s41596-024-01134-4 · Cited by 54
Adverse events following mRNA SARS-CoV-2 vaccination among U.S. nursing home residents
Bardenheier, B. H., Gravenstein, S., Blackman, C., Gutman, R., Sarkar, I. N., Feifer, R. A., White, E. M., McConeghy, K. W., Nanda, A., & Mor, V. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.088 · Cited by 56
Huang, A., Cicin‐Sain, C., Pasin, C., Epp, S., Audigé, A., Mueller, N. J., Nilsson, J., Bankova, A. K., Wolfensberger, N., Vilinovszki, O., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.01.019 · Cited by 58
Immunosenescence and Altered Vaccine Efficiency in Older Subjects: A Myth Difficult to Change
Fülöp, T., Larbi, A., Pawelec, G., Cohen, A. A., Provost, G., Khalil, A., Lacombe, G., Rodrigues, S., Desroches, M., Hirokawa, K., et al. (2022) · Vaccines · doi:10.3390/vaccines10040607 · Cited by 61
An Overview of the Use of Nanoparticles in Vaccine Development
Lozano, D., Larraga, V., Vallet‐Regí, M., & Manzano, M. (2023) · Nanomaterials · doi:10.3390/nano13121828 · Cited by 66
Zhou, Z., Wang, H., Li, J., Jiang, X., Li, Z., & Shen, J. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.127911 · Cited by 61
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 61
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 60
Keshavarz, B., Richards, N. E., Workman, L. J., Patel, J., Muehling, L. M., Canderan, G., Murphy, D. D., Brovero, S. G., Ailsworth, S. M., Eschenbacher, W. H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850987 · Cited by 61
Ultrasonic particles: An approach for targeted gene delivery
Walsh, A. P. G., Gordon, H. N., Peter, K., & Wang, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113998 · Cited by 59
Pardieck, I. N., van der Sluis, T. C., van der Gracht, E. T. I., Veerkamp, D. M. B., Behr, F. M., van Duikeren, S., Beyrend, G., Rip, J., Nadafi, R., Nejad, E. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31721-6 · Cited by 62
Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54
Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity
Dietz, L. L., Juhl, A. K., Søgaard, O. S., Reekie, J., Nielsen, H., Johansen, I. S., Benfield, T., Wiese, L., Stærke, N. B., Jensen, T. Ø., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00277-x · Cited by 56
Simmons, L. A., Whipps, M. D. M., Phipps, J. E., Satish, N. S., & Swamy, G. K. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.044 · Cited by 63
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Tang, P., Al Kanaani, Z., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003879 · Cited by 54
Park, J. K., Lee, E. B., Shin, K., Sung, Y., Kim, T., Kwon, S., Lee, M. S., Hong, S., Choi, B. Y., Lee, S., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e95 · Cited by 56
Bolze, A., Neveux, I., Barrett, K. M. S., White, S. J., Isaksson, M., Dabe, S., Lee, W., Grzymski, J. J., Washington, N. L., & Cirulli, E. T. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100084 · Cited by 63
Revolutionising health care: Exploring the latest advances in medical sciences
Mahara, G., Tian, C., Xu, X., & Wang, W. (2023) · Journal of Global Health · doi:10.7189/jogh.13.03042 · Cited by 77
Innate and adaptive immune responses toward nanomedicines
Viana, I. M. D. O., Roussel, S., Defrêne, J., Lima, E. M., Barabé, F., & Bertrand, N. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.022 · Cited by 63
Jochum, S., Kirste, I., Hortsch, S., Grunert, V. P., Legault, H. M., Eichenlaub, U., Kashlan, B., & Pajón, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.798117 · Cited by 58
The way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 58
Kiem, C. T., Massonnaud, C., Lévy-Bruhl, D., Poletto, C., Colizza, V., Bosetti, P., Fontanet, A. L., Gabet, A., Olié, V., Zanetti, L. C. D. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101001 · Cited by 61
COVID-19 vaccines: implementation, limitations and opportunities
Richman, D. D. (2021) · Global Health & Medicine · doi:10.35772/ghm.2021.01010 · Cited by 55
Narayanaswamy, V., Pentecost, B. T., Schoen, C. N., Alfandari, D., Schneider, S. S., Baker, R., & Arcaro, K. F. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004661 · Cited by 60
Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells
Liu, G. W., Guzman, E. B., Menon, N., & Langer, R. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03471-7 · Cited by 61
Lapointe, H. R., Mwimanzi, F. M., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Speckmaier, S., Moran-Garcia, N., Datwani, S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac229 · Cited by 75
Yazaki, S., Yoshida, T., Kojima, Y., Yagishita, S., Nakahama, H., Okinaka, K., Matsushita, H., Shiotsuka, M., Kobayashi, O., Iwata, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2159 · Cited by 56
Glatman-Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y., & Keinan-Boker, L. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103574 · Cited by 53
Correlates of Vaccine-Induced Protection against SARS-CoV-2
Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M., & Dahlke, C. (2021) · Vaccines · doi:10.3390/vaccines9030238 · Cited by 60
Soegiarto, G., Wulandari, L., Purnomosari, D., Fahmita, K. D., Gautama, H. I., Hadmoko, S. T., Prasetyo, M. E., Mahdi, B. A., Arafah, N., Prasetyaningtyas, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.059 · Cited by 66
Clinical progress of nanomedicine-based RNA therapies
Lim, S. A., Cox, A., Tung, M., & Chung, E. J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.10.018 · Cited by 73
Lombardi, A., Butta, G. M., Donnici, L., Bozzi, G., Oggioni, M., Bono, P., Matera, M., Consonni, D., Ludovisi, S., Muscatello, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100287 · Cited by 53
Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine
Özdemir, İ. H., Özlek, B., Özen, M. B., Gündüz, R., & Bayturan, Ö. (2021) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2021.04.018 · Cited by 59
Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population
Stephens, L. M., & Varga, S. M. (2021) · Vaccines · doi:10.3390/vaccines9060624 · Cited by 55
Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers
McLaurin‐Jiang, S., Garner, C. D., Krutsch, K., et al. (2021) · Breastfeeding Medicine · doi:10.1089/bfm.2021.0079 · Cited by 53
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
Schiffner, T., Phung, I., Ray, R., Irimia, A., Tian, M., Swanson, O., Lee, J. H., Lee, C.-C. D., Marina-Zárate, E., Cho, S. Y., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01833-w · Cited by 53
Ren, Y., Lin, L., Abdallah, M., Zhu, X., Liu, H., Fabb, S. A., Payne, T. J., Pouton, C. W., Johnston, A. P. R., & Trevaskis, N. L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113945 · Cited by 70
Zakarya, K. D., Бекболатович, К. Л., Orynbayev, M. B., Abduraimov, Y. O., Sultankulova, K. T., Kassenov, M. M., Sarsenbayeva, G., Кулмагамбетов, И. Р., Davlyatshin, T. I., Sergeeva, M. V., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101078 · Cited by 61
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 64
Ananworanich, J., Lee, I. T., Ensz, D. J., Carmona, L., Schaefers, K., Avanesov, A. S., Stadlbauer, D., Choi, A., Pucci, A., McGrath, S. M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae329 · Cited by 66
A panel dataset of COVID-19 vaccination policies in 185 countries
Cameron-Blake, E., Tatlow, H., Andretti, B., Boby, T., Green, K., Hale, T. N., Petherick, A., Phillips, T., Pott, A., Wade, A., et al. (2023) · Nature Human Behaviour · doi:10.1038/s41562-023-01615-8 · Cited by 61
Duration of immunity following full vaccination against SARS-CoV-2: a systematic review
Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 60
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
Opportunities and challenges for T cell-based influenza vaccines
Mosmann, T. R., McMichael, A. J., LeVert, A., McCauley, J. W., & Almond, J. W. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01030-8 · Cited by 57
COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy
Novelli, G., Biancolella, M., Mehrian‐Shai, R., Colona, V. L., Brito, A. F., Grubaugh, N. D., Vasiliou, V., Luzzatto, L., & Reichardt, J. K. V. (2021) · Human Genomics · doi:10.1186/s40246-021-00326-3 · Cited by 56
Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies
Berlansky, S., Sallinger, M., Grabmayr, H., Humer, C., Bernhard, A., Fahrner, M., & Frischauf, I. (2022) · Cells · doi:10.3390/cells11020253 · Cited by 53
Haskin, O., Ashkenazi‐Hoffnung, L., Ziv, N., Borovitz, Y., Dagan, A., Levi, S. S., Koren, G., Hamdani, G., Erez, D. L., Landau, D., et al. (2021) · Transplantation · doi:10.1097/tp.0000000000003922 · Cited by 52
A scalable and robust cationic lipid/polymer hybrid nanoparticle platform for mRNA delivery
Meyer, R. A., Hussmann, G. P., Peterson, N. C., Santos, J. L., & Tuesca, A. D. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121314 · Cited by 57
B Cell Response to Vaccination
Luo, W., & Yin, Q. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1903033 · Cited by 63
Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 49
Russo, G., Lai, Q., Poli, L., Perrone, M. P., Gaeta, A., Rossi, M., Mastroianni, C. M., Garofalo, M., & Pretagostini, R. (2021) · Clinical Transplantation · doi:10.1111/ctr.14495 · Cited by 51
Rapid characterization of spike variants via mammalian cell surface display
Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 56
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.